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5 Acute lymphoblastic leukaemia (ALL) is a haematological malignancy that is characterized 
6 
7 by the uncontrolled proliferation of immature lymphocytes. 80 % of cases occur in children 
8 
9 where ALL is well understood and treated. However it has a devastating affects on adults, 
10 where multi-agent chemotherapy is the standard of care with allogeneic stem cell 
12 transplantation for those who are eligible. New treatments are required to extend remission 
13 
14 and prevent relapse to improve patient survival rates. 
15 
16 We used serum profiling to compare samples from presentation adult B-ALL patients with 
17 age- and sex-matched healthy volunteer (HV) sera and identified 69 differentially recognised 
19 antigens (p≤0.02). BMX, DCTPP1 and VGLL4 showed no differences in transcription 
20 
21 between patients and healthy donors but were each found to be present at higher levels in B- 
22 
23 ALL patient samples than HVs by ICC. BMX plays a crucial role in the Bruton’s Tyrosine 
24 Kinase (BTK) pathway which is bound by the BTK inhibitor, ibrutinib, suggesting adult B- 
26 ALL would also be a worthy target patient group for future clinical trials. 
27 
28 We have shown the utility of proto-array analysis of B-ALL patient sera, predominantly 
29 
30 from young adults, to help characterise the B-ALL immunome and identified a new target 
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5 B-cell  acute  lymphoblastic  leukaemia  (B-ALL)  is  a  clonal  malignant  disease  that  is 
6 
7 characterised   by   the   accumulation   of   genetically   damaged   precursors   of   B  lineage 
8 
9 lymphocytes. This lineage of ALL affects immature B-cells, suppressing normal 
10 haematopoiesis and affecting the ability of healthy immature B-cells to differentiate and 
12 mature into functional B lymphocytes and plasma cells. Like all leukaemias, ALL rapidly 
13 
14 spreads throughout the body making localised treatments of little benefit. In addition, most 
15 adult ALL patients will achieve first remission but experience high relapse rates with long 




21 Immunotherapy is currently used to treat ALL patients through allogeneic haematopoietic 
22 
23 stem cell transplant and can improve overall survival for patients up to 27-65 % (Fielding et 
24 al., 2009, Goldstone et al., 2008, Moorman et al., 2007). To boost the graft versus host effect 
26 and maximise the chances of successful transplantation of the donor stem cells, patients are 
27 
28 given donor leukocyte infusions to support the graft. However, over one third of patients will 
29 
30 still relapse and the mortality rates associated with stem cell transplantations remain high. 
31 Additional immunotherapy strategies for B-ALL include those targeting CD20, a surface 
32 
33 marker of B-lineage lymphocytes present in 25 % of patients with pre-B ALL and nearly all 
34 
35 mature ALL cells (Wei et al., 2017). 
36 
37 Despite the number of existing therapies, new treatments targets need to be identified to 
38 further personalise treatments and enhance survival rates for patients with adult B-ALL. 
40 Antigen identification has the potential to extend the use of existing therapeutic strategies and 
41 
42 identify biomakers that enable more personalised treatment. To this end we used proto-arrays 
43 
44 that contain over 9,000 individally purified human proteins to determine the preferential 
45 recognition of antigens by antibodies in adult B-ALL patient sera. 
47 
48 
49 MATERIALS AND METHODS 
50 
51 Patient samples. Adult B-ALL samples were collected from patients, attending the 
52 
53 Departments of Haematology at Southampton University Hospitals Trust, Portsmouth 
54 
55 Hospitals NHS Trust and the Royal Devon and Exeter Foundation Trust, following informed 
56 consent and local ethical approval (REC 07/H0606/88). Leukaemic blasts, mononuclear cells 
58 and sera were isolated from bone marrow (BM) or peripheral blood (PB) and were collected 
59 
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3 in EDTA or from clotted blood. Sera and white blood cells were also isolated from age and 
4 
5 sex-matched healthy volunteer (HV) samples following informed consent and local ethical 
6 
7 approval (LREC 228/02/T), or provided by the North London Blood Transfusion Centre 
8 (NLBTC) and all samples were stored at -80oC for later use. Red blood cells were lysed using 
10 red cell lysis buffer, the cells were washed in phosphate buffered saline and either 2.5 x 104 
11 
12 spotted onto two sites on glass slides and allowed to dry for 4-16 h prior to being double 
13 wrapped in cling film and stored at -20oC for ICC or snap-frozen as pellets at 105-106 cells 
5 per tube at -80oC. 
16 
17 Cell culture. Cell lines were obtained from and cultured as per ATCC instructions. Cell lines 
18 
19 were cultured in RPMI 1640 (K562) or DMEM (Hek293T, MDA-MB-231 and MDA-MB- 
20 




Serum profiling using protein microarrays. We performed serum profiling on 13 samples 
26 from nine B-ALL patients, eight of which were prior to treatment, as well as nine age and 
27 
28 sex-matched HV samples (Table 1). Each ProtoArray - Human Protein Microarray v5.0 (Life 
29 
30 Technologies) slide was immunoscreened with a single serum sample while one ProtoArrayR 
31 Control Microarray (Life Technologies) was used with control protein and one slide was 
32 
33 assayed with secondary antibody alone. Signals from all peptides were analysed on the 
34 
35 ProScanArray (PerkinElmer) using ProtoArray® Prospector v5.2 software (Life 
36 Technologies). 
38 
Prioritisation of B-ALL antigens. To determine which genes warranted further investigation, 
40 we examined the antigens that were more frequently recognised by antibodies in sera from 
41 
42 adult B-ALL than age- and sex-matched HV samples (at a p value of ≤0.02) using a 
43 
44 systematic peer review process [described in (Cooksey, 2018)]. Briefly, we used Scopus and 
45 NCBI, and the search terms used were, where X represents each protein individually, ‘X’, ‘X 
47 AND cancer’, ‘X AND leukaemia’, ‘X AND ‘acute lymphoblastic leukaemia’’, ‘X AND 
48 
49 function’; where available appropriate aliases were also searched in the same manner. In 
50 addition we performed STRING analysis (https://string-db.org/) to identify the processes 
52 these antigens engage in that are involved in cancer. 
53 
54 cDNA preparation from human samples. To evaluate the expression of the most promising 
55 
56 antigens in HV and B-ALL cells, we isolated RNA from BM and PB samples using QIAGEN 
57 
58 RNeasy® Plus mini kit (QIAGEN Ltd.) according to the manufacturer’s protocol. cDNA was 
59 
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3 prepared  using  the  MBI  Fermentas  RevertAid  First  Strand  cDNA  synthesis  kit  (MBI 
4 
5 Fermentas  Ltd,  Helena  BioSciences  Ltd,  Sunderland,  U.K.)  which  was  DNase  I treated 
6 
7 (Roche Products Ltd, Herts, U.K.), cleaned using a RNeasy kit (Qiagen), checked on a 1 % 
8 agarose-TBE gel and quantified using a NanoDrop™ Lite Spectrophotometer (Thermo 
10 Scientific, UK). 
11 
12 Quantitative–Polymerase Chain Reaction (qPCR) analysis. QPCR was performed using 
13 
14 QuantinovaTM SYBR® Green kit and QuantiTect Primers (all Qiagen). Glyceraldehyde 3- 
15 phosphate dehydrogenase (GAPDH) and TATA-box binding protein (TBP) were used as 
17 reference genes, chosen based on previous publications (Lossos et al., 2002) and in keeping 
18 
19 with MIQE guidelines (Bustin et al., 2009, Bustin and Wittwer, 2017). Each primer was 
20 
21 tested on at least one human cancer cell line that was known to express that antigen of 
22 interest (Table 2). 
24 
To control for gDNA contamination within the qPCR reagents, a no cDNA control was 
26 included on every qPCR plate whereby cDNA was replaced by RNase-free H2O. In addition, 
27 
28 each sample was analysed in triplicate on the 96-well qPCR plate (Applied Biosystems, 
29 
30 USA). The reaction volumes were 10 µL 2X QuantiNova SYBR green PCR Mix, 2 µL QN 
31 ROX reference dye, 2 µL QuantiTect primer assay and 5 µL RNase-free H O, making a total 
32 
33 volume of 19 µL added to each well in the 96-well plate. In 1 µL final volume, ≤100 ng of 
34 
35 template cDNA was added to achieve a final volume of 20 µl. The plate was then loaded into 
36 the thermocycler (StepOne Plus Real-Time PCR system, Applied Biosystems). 
38 
The cycle was 2 minutes at 95°C, then 40 cycles of 5 s at 95°C followed by 10 s at 60°C. 
40 This was immediately followed by a melt curve stage of 15 s at 95°C, 1 min at 60°C and 15 s 
41 
42 at 95°C, to verify the specificity of the amplification. Data was compared using StepOne 
43 
44 software v2.0 (Applied Biosystems) and the comparative CT method.(Livak and Schmittgen, 
45 2001) We used the relative quantification (also comparative CT) method to analyse the qPCR 
47 data. 
48 
49 Immunocytochemistry. Immunocytochemistry was performed as described previously(Khan 
50 
51 et al., 2015) using the antibodies detailed (Supplementary Table A1). Actin was used as a 
52 positive control for the successful performance of ICC while isotype, no primary and no 
54 secondary antibody immunolabelling acted as negative controls, used to detect non-specific 
55 
















3 Staining  intensities  were  scored  according  to  a  five-tiered  scale  [described  originally by 
4 
5 (Biesterfeld et al., 1996)] as follows:- 0: no staining; 1: background; 2: weak staining; 3: 
6 
7 moderate staining; 4: strong staining. The percentage of positively stained cells was based on 
8 the cell count of stained cells per microscopic view, and represented on a five-tiered scale (0: 
10 0 %; 1: 1-10 %; 2: 11-50 %; 3: 51-80 %; 4: > 80 %). The final immunoreactivity score was 
11 
12 obtained by multiplication of the percentage of positive stained cells per microscopic view by 
13 the value for staining intensity (0 = negative, 1-29 = weak, 30-143 = moderate, 144-228 = 
5 high and > 228 = very high staining)(Deng et al., 2014). 
16 
17 Microarray analysis of gene expression and clinical parameters. Finally we analysed a 
18 
19 publically available microarray expression data (GSE38403)(Geng et al., 2012) which 
20 
21 encompassed 215 adult B-cell ALL and 12 pre-B samples (CD19+ and VpreB+) isolated 
22 from the bone marrows of HVs. For microarray analysis, the files were imported from GEO 






30 Serum profiling using proto-arrays. The intensity values were used to undertake a per chip / 
31 
32 per gene normalisation process and then ANOVA was performed on the 3,998 proteins, that 
33 had showed differences in recognition by HV and patient sera, across the 22 samples 
35 analysed (excluding the control). ANOVA analysis identified 69 significant genes that had a 
36 
37 p<0.05 in terms of their recognition by ALL versus HV sera (Supplementary Table A2). 
38 
39 The mean value and standard deviation of each signal was calculated to produce a z-score 
40 and showed that 19 proteins were more frequently recognised (Supplementary Table A2i) 
42 and 50 proteins were less frequently recognised by antibodies in B-ALL (Supplementary 
43 
44 Table A2ii) compared with HV sera. Two proteins that had fold changes of less than 1.5 
45 
46 (POLK3K and RAB2IL1) were included as they were significantly different in their 
47 recognition by ALL versus HV sera. However, we focussed on antigens that were more 
49 frequently recognised by antibodies in B-ALL than HV sera because of our interest in 
50 
51 identifying antigenic targets for immunotherapy. 
52 
53 Hierarchical cluster analysis was performed using Wards method (Fig 1A) and showed that 
54 B-ALL patients could be differentiated from HVs on the basis of protein recognition by sera. 
56 Principal component analysis (PCA)(Fig 1B) showed that apart from one HV sample, there 
57 
58 was a good cluster distinction between the proteins recognised significantly more or less 
59 
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3 frequently by ALL compared with HV sera.   Interestingly, the ALL cluster in the PCA plot 
4 
5 is “tighter” than the HV cluster probably reflecting the homogeneity of the proteins uniquely 
6 
7 recognised by B-ALL sera and the relative heterogeneity of the proteins recognised by 
8 antibodies in the HV samples. 
10 Prioritisation of proto-array identified antigens. Through a systematic review of the literature 
12 (Cooksey, 2018) we identified bone marrow tyrosine kinase on chromosome X (BMX) also 
13 
14 known as epithelial and endothelial tyrosine kinase (Ekt), dCTP pyrophosphatase 1 
15 (DCTPP1) also known as XTP3-transactivated protein A (XTP3TPA) and vestigial like 4 
17 (VGLL4) for further expression analysis. Each antigen was investigated by STRING analysis 
18 
19 and shown to have pathways associated with subverted processes in cancer (Fig 2A). These 
20 
21 three antigens were then analysed for their expression in samples from adult B-ALL and HVs 
22 by qPCR and ICC. 
24 
qPCR analysis of antigen expression in B-ALL and HV samples. We determined the relative 
26 expression of transcripts encoding the antigens of interest in the following cell lines that we 
27 
28 used as controls (K562, HEK293T, MDA-MB-231 and MD-MB-468)(Table 2). We included 
29 
30 survivin in this study based on the promising results we had observed with this antigen, in 
31 terms of elevated expression, in B-ALL compared with HV samples previously (Boullosa et 
32 
33 al., 2018). All cell lines expressed all housekeeping genes as well as the four antigens under 
34 
35 investigation, except BMX which was not expressed in any of the cells lines. 
36 
37 All samples from B-ALL patients and HVs, except for HV025, showed convincing GAPDH 
38 expression (Table 3) and all antigens tested (BMX, DCTPP1, survivin and VGLL4) were 
40 expressed at lower levels than GAPDH, as expected. Survivin was expressed at higher levels 
41 
42 than TBP in all cell lines, and DCTPP1 and VGLL4 were expressed at higher levels than 
43 
44 TBP in K562 and Hek293T. TBP was recommended as a housekeeping gene for qPCR by 
45 other studies however we found TBP expression was not consistent between the samples. 
47 However the differences in expression between the HV samples were much smaller, after 
48 
49 excluding HV025 from our analysis. 
50 
51 Patients ALL005 and ALL019 were not found to express detectable levels of any of the 
52 antigens studied (BMX, DCTPP1, survivin and VGLL4)(Fig 2B) while ALL020 (PB and/or 
54 BM) expressed all four antigens. Of the other B-ALL patient samples analysed, two had 
55 
56 detectable BMX expression (ALL008 and ALL020 PB), three patients expressed DCTPP1 
57 
58 (ALL007, ALL008 and ALL020 BM) and three patients expressed VGLL4 and survivin 
59 
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3 (ALL007, ALL008 and ALL020 PB and BM). ALL007 and ALL008 had also been examined 
4 
5 by  our  group  previously  (Boullosa  et  al.,  2018)  and  while  ALL007  was  found  to have 
6 
7 detectable survivin transcripts in both studies, ALL008 was negative for detectable survivin 
8 transcripts in our previous study. None of the HVs had consistently detectable levels of 
10 BMX, while all expressed DCTPP1 and VGLL4. In contrast to our previous findings, where 
11 
12 four of five HVs did not express detectable levels of survivin in this study transcripts were 
13 detected in three of four HVs (whom we had not analysed previously). 
15 
Immunolabelling of antigen expression in B-ALL using immunocytochemistry. We used actin 
17 as a positive control for immunolabelling and found it, as expected, to be present in all four 
18 
19 control cell lines at high levels (Table 2), while the negative controls for this experiment 
20 
21 (cells only, no primary antibody and isotype control) were all negative. HEK293T cell line 
22 was used to demonstrate we could immunolabel BMX (van Oosterwijk et al., 2018) and 
24 VGLL4 (Jiao et al., 2017), but only showed a moderate cytoplasmic expression of BMX and 
25 
26 were negative for VGLL4; weak immunolabelling of survivin was also detected. The K562 
27 
28 cell line was used to demonstrate the immunolabelling of DCTPP1 (Song et al., 2015) and 
29 survivin (Schmidt et al., 2003), and showed moderate cytoplasmic levels of both. MDA-MB- 
31 231 cell line was used to demonstrate we could immunolabel DCTPP1 (Song et al., 2015), 
32 
33 while MDA-MB-468 was chosen as an immunolabelling control for VGLL4 (Zhang et al., 
34 2017), but both were negative for the detection of these antigens. Of note VGLL4 was not 
36 found in any cell line, MDA-MB-231 and MDA-MB-468 did not express DCTPP1 or 
37 
38 survivin, while each had transcripts from these antigens that were detectable by qPCR. In 
39 
40 contrast BMX was detectable in Hek293T by ICC in agreement with previously published 
41 Western blotting data (van Oosterwijk et al., 2018). 
43 Each antigen was found at moderate to high levels in patient samples (BMX - 4 of 6; 
45 DCTPP1 – 2 of 2; survivin - 1 of 2 and VGLL4 - 1 of 2) while each antigen was only found 
46 
47 at low levels in HV samples (n=7)(Table 4; Fig 3). Of note ALL005 had also been examined 
48 for survivin expression in our previous study and was found to be positive by ICC in this 
50 study also. 
51 
52 Gene expression microarray analysis. The antigens that were significantly more frequently 
53 
54 recognised by B-ALL than HV sera (p≤0.02) and were present in the microarray database 
55 
56 (GSE38403)(Geng et al., 2012) was examined for their association with above and below 
57 median levels of expression at disease diagnosis, and overall patient survival in the following 
59 
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3 5 years post-diagnosis. Only cyclin G associated kinase (GAK) and high mobility group box 
4 
5 family member 2 (TOX2) showed a significant association between above median expression 
6 
7 at  disease  diagnosis  and  5-year  overall  survival  (p=0.024  and  p=0.0056 LogRank  and 
8 p=0.056 and p=0.028 by Wilcoxon-Gehan, repectively; Fig 4A). When we analysed the 
10 levels of expression, segregated into quartiles, we found that only expression of TOX2 in the 
11 
12 third quartile (Q3 - above median-low) was associated with 5 year survival while expression 
13 in the top quartile (Q4 - above median-high) was not (Fig 4B). 
15 
In addition a number of clinical features (stage and cytogenetic abnormalities) were found to 
17 be  significantly  associated  with  above  or  below  median  antigen  expression  at  disease 
18 
19 diagnosis (Supplementary Table A3). Of particular note was the high level of statistical 
20 
21 significance (p<0.001) for the following antigens and gender (BMX), stage (APOBEC3A, 
22 DCTPP1, MUC20, SEPT9, TOX2 and WARS), early pre-B versus mature B-ALL (WARS), 
24 early pre-B versus early Pro-B (DCTPP1, MUC20, SEPT9, TOX2), early pre-B versus 
25 
26 transitional Pre-B (VGLL4), mature B-ALL versus Pro-B (APOBEC3A), pre-B-ALL versus 
27 
28 pro-B (MUC20), MLL mutation (DCTPP1, MUC20 and TOX2), BCR-ABL (DCTPP1, 
29 IGLL1, LMX1a, TOX2 and VGLL-4), other cytogenetic abnormalities (LMX1A), no 










41 Despite the recent development of a number of strategies for the treatment of adult B-ALL, 
42 survival rates remain low. This is mostly due to the toxicity of treatment to older adult B- 
44 ALL patients, the absence of B-ALL cell specific therapies, co-morbidities associated with 
45 
46 the level of fitness of patients, treatment related toxicities and death due to disease 
47 
48 recurrence. The circumvention of relapse due to improved treatments including matched 
49 unrelated stem cell transfusions, donor lymphocyte infusions and more recent 
50 
51 immunotherapy strategies have had significant impacts on patient survival but they still have 
52 




As part of the effort to identify new targets for immunotherapy, that can help delay if not 
58 prevent relapse after first remission, and to help us better understand the biological basis of 
59 
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3 adult B-ALL, we sero-profiled adult B-ALL patients and age and sex-matched HV sera. We 
4 
5 identified three antigens that had been shown to play a significant role in cancer(s) and 
6 
7 examined their expression in patient and HV samples. We have previously shown that 
8 survivin had significantly higher expression in B-ALL samples compared with healthy 
10 controls by qPCR analysis (p=0.015) and gene expression analysis (p = 0.013)(Boullosa et 
11 
12 al., 2018). However there were no statistically significant differences between the expression 
13 of the four antigens examined in this study (BMX, DCTPP1, survivin or VGLL4) in patient 
5 samples compared with HVs by qPCR. Gene expression array analysis confirmed that BMX, 
16 
17 DCTPP1, survivin and VGLL4 transcript levels were not different between B-ALL patients 
18 
19 compared with healthy donors (data not shown), while ICC analysis showed elevated protein 
20 levels in patients compared with healthy donors. 
22 
The discordance between detection of transcripts by qPCR and immunolabelling of antigens 
24 by ICC has been observed by scientists in other fields of research.  It appears that there is a 
25 
26 linear relationship between gene transcription and protein levels in Drosophila, (Lemos et al., 
27 
28 2005) that uncouples with evolutionary complexity, maximising in chimpanzees and humans 
29 (Fu et al., 2007) and is partially explained by post-transcriptional regulation and differences 
31 in mRNA and protein turnover rates. Although qPCR is often used to semi-quantitate gene 
32 
33 expression, we found that protein levels, the ultimate target of immunotherapy strategies, are 
34 a more convincing indicator of the presence of an antigen in a cell. 
36 
BMX was more frequently recognised by B-ALL patient compared to HV sera (p=0.035) and 
38 is a particularly appealing target for immunotherapy, in accordance with the National Cancer 
39 
40 Institute (NCI) priority list (Cheever et al., 2009), by virtue of it’s location on the X 
41 
42 chromosome. In addition, BMX has been shown to play a central role in the immune 
43 response, inflammation and cytokine signalling by regulating TNF-dependent signalling at a 
45 central node, that affects the efferent signalling branches of JNK, p38 MAPK and NK-kappa- 
46 
47 B (Gottar-Guillier et al., 2011, Holopainen et al., 2012, Li et al., 2017). BMX has been 
48 reported to regulate multiple proteins (Saharinen et al., 1997, Chen et al., 2013, Holopainen et 
50 al., 2012, Wang et al., 2017, Li et al., 2017) and these associations were confirmed by our 
51 
52 STRING analysis. As a tyrosine kinase BMX is a target for inhibitors including CI-1033, an 
53 
54 epidermal growth factor receptor (EGFR) inhibitor, BMX-IN-1 (Liu et al., 2013) and CTN06 
55 (Guo et al., 2014), a small molecule dual inhibitor of BMX and Bruton’s Tyrosine Kinase 
















3 inhibition of the growth and migration of prostate cancer cells.  In addition, BMX is a target 
4 
5 of ibrutinib, a small molecule therapy that targets the BTK pathway. Ibrutinib is being used in 
6 
7 several clinical trials for patients with mature B-cell malignancies including 
8 relapsed/refractory chronic lymphocytic leukaemia (Coutre et al., 2019, Nuttall et al., 2019, 
10 Shanafelt et al., 2019), small lymphocytic lymphoma (Coutre et al., 2019), and mantle cell 
11 
12 lymphoma (Wang et al., 2013) and BMX expression in 4/6 adult B-ALL patients in this 
13 study, the antigenicity of BMX as shown by proto-array analsys and recent study showing the 
5 ability of ibrutinib to target pre-BCR signalling in B-ALL (Kim et al., 2017) all suggest the 
16 
17 value of using ibrutinib to treat adults with B-ALL. 
18 
19 The other two antigens investigated were DCTPP1 an intracellular regulator of 5-methyl- 
20 
21 dCTP metabolism that has been associated with DNA hypermethylation and gene silencing 
22 (Song et al., 2015). DCTPP1 is downregulated when the PI3K/AKT/mTOR pathway is 
24 activated and autophagy activity is suppressed (Lu et al., 2018) with its’ expression being 
25 
26 associated with poor prognosis and lower overall survival of solid cancer patients (Zhang et 
27 
28 al., 2013, Morisaki et al., 2014, Song et al., 2015, Lu et al., 2018). DCTPP1 has also been 
29 shown to increase chemotherapy resistance in gastric cancer suggesting a role as a indicative 
31 biomarker of chemoresistance in patients (Xia et al., 2016). VGLL4 is a tumour suppressor 
32 
33 gene located on 3p25.3-3p25.2 and was deemed worthy of further investigation because of 
34 it’s roles in proliferation, migration and cell death in a number of cancer types (Deng and 
36 Fang, 2018). VGLL4 is a co-factor for TEA domain-containing transcription factors 
37 
38 (TEADs)(Zhang et al., 2017) and this association was re-itterated by our STRING analysis. 
39 
40 It was also notable that WWOX appeared as one of the antigens that was less frequently 
41 
42 recognised by patient than HV sera and this correlated with previous findings that WWOX 
43 was partially expressed or absent in over half of haematopoietic malignancies tested (Ishii et 
45 al., 2003, Cui et al., 2013). Some debate remains as to whether WWOX is affected in 
46 
47 leukaemias by virtue of it’s location on 16q23.3-24.1 in the common fragile site FRA16D, 
48 however recent studies have shown reduced WWOX expression in leukaemia cells, with 
50 WWOX inhibition repressing proliferation and increased rates of apoptosis (Lin et al., 2013). 
51 
52 Due to the relative rarity of adult B-ALL (Inaba et al., 2013) we used exisiting gene 
53 
54 expression data (GSE38403)(Geng et al., 2012) to examine associations between gene 
55 
56 transcript levels, disease stage and cytogenetic abnormalities. Only two antigens, GAK and 
57 TOX2, had above median expression at disease diagnosis that significantly correlated with 
59 
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3 improved  overall  survival.  We  have  seen  similar  results  previously  in  acute  myeloid 
4 
5 leukaemia (AML) at disease presentation with SSX2IP, RHAMM and survivin (Guinn et al., 
6 
7 2009) and reasoned that the elevated antigen expression could induce enhanced anti-tumour 
8 responses in patients following conventional treatment. We propose that as dead and dying 
10 leukaemia cells are mopped up by immune cells and their peptide contents are presented on 
11 
12 MHC in the context of ‘danger’ (inflammation) leading to more effective anti-tumour 
13 responses. However this isn’t always the case with antigens such as PRAME showing a 
5 Goldilocks effect in terms of both very high and very low expression being associated with 
16 
17 poor survival in myelodysplastic syndome patients (Liberante et al., 2013), perhaps reflecting 
18 
19 the impact of high PRAME expression on tumourigenicity and low PRAME levels enabling 
20 immune evasion following conventional treatment. 
22 
In summary, we have used serum profiling for the first time to characterise the recognition of 
24 antigens by antibodies in adult B-ALL sera, in direct comparison to age and sex-matched HV 
25 
26 sera. We have identified new targets for treatment (BMX), provided new insights into the the 
27 
28 biology underlying this rare and difficult to treat disease (loss of WWOX antigen recognition 










































5 AML: acute myeloid leukaemia; B-ALL: B-cell acute lymphoblastic leukaemia; BMX: bone 
6 
7 marrow tyrosine kinase on chromosome X; BTK: Bruton’s Tyrosine Kinase; CAR: chimeric 
8 
9 antigen receptor; DCTPP1: dCTP pyrophosphatase 1; GAK: cyclin G associated kinase; 
10 GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; HV: healthy volunteer; PB: peripheral 
12 blood; PCA: Principal component analysis; qPCR: quantitative polymerase chain reaction; 
13 
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3 Fig 1 Immunoprofiling using sera from adult B-ALL patients and HVs. (A) Hierarchal 
4 Clustering of proteins shows that adult B-ALL and HV samples may be differentiated based 
5 on antibody recognition of antigens and that antigen recognition to adult B-ALL sera (blue 
6 box) may be less heterogeneous than previously thought; (B) PCA evidences the distinctness 




12 Fig 2. Analysis of the protein interactions and gene expression of prioritised antigens. 
13 (A) STRING analysis identified the experimentally determined protein interactions by each 
15 antigen of interest (represented as a red ball). Panel (i) BMX showed interactions with 
16 multiple components involved in cell-adhesion, cell growth, cell survival, signaling pathways 
17 and apoptosis, including ES1, FYN, SRC and CASP3; Panel (ii) DCTPP1 (red ball) interacts 
19 with NME1 and 2. NME1 is involved in cell proliferation, differentiation and development 
20 while NME2 acts as a transcriptional activator for the MYC gene, a family of regulator genes 
21 and proto-oncogenes; Panel (iii) VGLL4 interacts with TEA domain family members 
23 (TEAD1, 2 and 4), transcriptional factors that play key roles in the Hippo signaling pathway. 
24 The Hippo pathway is involved in controlling tumor suppression by restricting proliferation 
25 and promoting apoptosis; (B) Expression of each antigen is shown as follows (i) BMX; (ii) 
27 DCTPP1; (iii) Survivin and (iv) VGLL4 relative to GAPDH as determined by qPCR. 
28 
29 
30 Figure 3. Immunolabelling to detect expression of the prioritised antigens in primary 
31 adult B-ALL patient samples. Blue arrows indicate the B-ALL patient cells that show 
33 antigen expression (also indicated by the formation of a brown precipitate). Actin acted as the 
34 positive control for immunolabelling. The two isotype matched antibodies were used as 
35 negative controls. Panel (A) shows patient and HV samples immunolabelled for expression of 
36 BMX, DCTPP1, survivin and VGLL4 while panel (B) shows samples immunolabelled for 
37 BMX expression and with isotype control antibody only. Percentages shown are the averages 
38 of  positively  stained  cells  of  the  ‘n’  independent  experiments.  The  blue  arrows  point at 
39 positive stained cells and the blue squares contain one-cell-zoom pictures from the original 
41 picture (scale bar is 100µm). All pictures were taken at 400X magnification. 
42 
43 
44 Fig 4. Gene expression microarray analysis of antigen expression and overall survival 
45 (over 5 years) in adult B-ALL patients. Overall survival was found to be significantly 
46 associated with above median (high) levels of (A)(i) TOX2 (Log-Rank p-value = 0.075; 
47 Wilcoxon-Gehan p-value = 0.034) and (ii) GAK (Log-Rank p-value 0.024; Wilcoxon-Gehan 
49 p-value = 0.034); When expression levels were divided into quartiles (B) Q1 represents low- 
50 low level expression, Q2 median-low; Q3 median-high and Q4 high-high levels of expression, 
51 relative to the median. (i) TOX2 expression was significantly associated with improved 
52 survival for the patients expressing median-high (Q3) levels of expression (Log-Rank p-value 
53 0.011; Wilcoxon-Gehan p-value = 0.032) but not for patients expressing the high-high levels 
54 (Q4). The same association was not seen with (ii) GAK expression although a trend towards 
55 improved survival was seen in patients with the high-high levels of expression (Log-Rank p- 


































































ID Disease stage Age 
(at sampling) 
Sex HV control† Age Sex 
ALL001 Diagnosis – Ph+ ALL 39 M HV013 40 M 
ALL002 Follow-up 19 M HV007 19 M 
ALL003 Diagnosis 26 F HV006 26 F 
ALL003-FU Follow-up - 4 months post-allo 26 F HV006 26 F 
ALL004 Diagnosis 22 M HV015 22 M 
ALL005 Diagnosis 64 M HV009 64 M 
ALL007 Diagnosis 19 M HV007 19 M 
ALL008 Pre-treatment 19 F HV011 19 F 
ALL009 Diagnosis 49 M HV014 45 M 
ALL009-FU Follow-up – 4 months post-allo 49 M HV014 45 M 
ALL010 Diagnosis 19 M HV015 22 M 
ALL010-FU Follow-up 19 M HV015 22 M 
ALL017 Post-treatment 46 M  
ALL018 Pre-treatment 37 F 
ALL019 Pre-treatment, hyperdiploid 18 F 
ALL020 Pre-treatment 33 M 




3 Table 2. Cell line controls used for qPCR and ICC analysis of the antigens of interest, existing results on expression from the literature and corresponding qPCR and ICC 










































Cell line Antigens 
expressed 
qPCR data ICC data* 
GAPDH TBP BMX DCTPP1 Survivin VGLL4 Actin BMX DCTPP1 Survivin VGLL4 
Hek293T BMX 
VGLL4 
















MDA-MD-231 DCTPP1 + + - + + + + 
Weak 
- - - - 
MDA-MD-468 VGLL4 + + - + + + + 
Mod 
- - - - 
 Total 4/4 4/4 0/4 4/4 4/4 4/4 3/4 1/4 1/4 1/4 0/4 
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16 Data is representative of two independent experiments. GAPDH and TBP were used as reference genes. +, antigen expression; +/-, one experiment showed no expression while the second 
17 showed expression; -, no antigen expression. *The total number of patients that expressed the antigen is shown at the bottom of the table, in this result the ± samples are excluded. (#): results 




























Patients GAPDH TBP BMX DCTPP1 VGLL4 Survivin (#) HVs GAPDH TBP BMX DCTPP1 VGLL4 Survivin 
ALL005 + - - ± - - HV023 + + - + + + 
ALL007 + ± - + + + (+) HV024 + + - + + + 
ALL008 + ± + + + + (-) HV025 ± ± ± + + ± 
ALL019 PB + - - - - ± HV026 + + ± + + + 
ALL020 PB + + + ± + + Total 3/4 3/4 0/2 4/4 4/4 3/4 
ALL020 BM + + ± + + +  
Total* 5/5 1/5 1/5 3/5 3/5 3/5 
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3 Table 4. Immunoreactivity scores (and immunolabelling intensity in parenthesis) of the antigens of interest in (A) cell lines and (B) primary samples as 
4 










































samples BMX DCTPP1 VGLL4 Survivin HVs BMX DCTPP1 VGLL4 Survivin 
ALL003 49 (Moderate) ND ND ND HV027 0 (Negative) 15 (Weak) 0 (Negative) 22 (Weak) 
ALL004 91 (Moderate) 59 (Moderate) 154 (High) 68 (Moderate) HV028 22 (Weak) 3 (Weak) 0 (Negative) 11 (Weak) 
ALL005 23 (Weak) 35 (Moderate) 20 (Weak) 15 (Weak) HV029 0 (Negative) 0 (Negative) 0 (Negative) 0 (Negative) 
ALL007 1 (Weak) ND ND ND HV030 0 (Negative) 0 (Negative) 0 (Negative) 0 (Negative) 
ALL008 84 (Moderate) ND ND ND HV031 0 (Negative) 20 (Weak) 0 (Negative) 10 (Weak) 
ALL017 73 (Moderate) ND ND ND HV032 0 (Negative) 0 (Negative) 0 (Negative) 0 (Negative) 
Total* 4/6 2/2 1/2 1/2 HV033 0 (Negative) 0 (Negative) 0 (Negative) 0 (Negative) 
 Total* 0/7 0/7 0/7 0/7 
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3 Supplementary data 














































Primary antibodies       
Actin AC-15 Mouse anti-human Monoclonal, IgG1 sc-69879 Santa Cruz Biotechnology; 1/100 
     Santa Cruz, CA (USA)  
BMX Y396 Rabbit anti-human Monoclonal, IgG ab32153 Abcam 1/100 
DCTPP1 A10058 Rabbit anti-human Polyclonal, IgG HPA002832 Sigma-Aldrich 1/100 
Survivin EP2880Y Rabbit anti-human Monoclonal, IgG ab76424 Abcam 1/100 
VGLL-4 N/A Rabbit anti-human Polyclonal, IgG ab243518 Abcam 1/100 
Isotype control for actin MOPC-21 Mouse anti-human Monoclonal, IgG1 ab18443 Abcam 1/250 
Isotype control for BMX, 
DCTPP1, Survivin, 
SP137 Rabbit anti-human Monoclonal, IgG1 ab125938 Abcam 1/250 
VGLL4       
Secondary antibodies*       
Anti-mouse  Anti-mouse Polyclonal, Ig K4007 Dako N/A 
Anti-rabbit  Anti-rabbit Polyclonal, Ig K4011 Dako N/A 
 




































3 Table A2 Analysis of the antigens that were differentially recognised by patient compared with HV sera identified antigens that were (i) more 























































GCC1 GRIP and coiled-coil domain-containing protein 1 0.016 0.57 -1.76 
VGLL4 vestigial like 4 (Drosophila) 0.020 0.36 -2.76 
ACOX1 acyl-Coenzyme A oxidase 1, palmitoyl (ACOX1) 0.022 0.69 -1.45 
APOBEC3A apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A 0.022 0.58 -1.73 
TOX2 TOX high mobility group box family member 2, transcript variant 3 0.024 0.69 -1.45 
MUC20 Mucin-20 0.025 0.43 -2.32 
WARS Tryptophanyl-tRNA synthetase, cytoplasmic 0.025 0.49 -2.03 
DCTPP1 XTP3-transactivated protein A 0.027 0.58 -1.73 
GAK cyclin G associated kinase 0.030 0.47 -2.11 
SEPT9 septin 9 0.031 0.55 -1.81 
CDC42EP1 Cdc42 effector protein 1 0.033 0.57 -1.77 
BMX BMX non-receptor tyrosine kinase, transcript variant 2 0.035 0.65 -1.55 
IGLL1 immunoglobulin lambda-like polypeptide 1, transcript variant 1 0.039 0.73 -1.36 
NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase) 0.044 0.74 -1.35 
LMX1A LIM homeobox transcription factor 1, alpha 0.046 0.39 -2.55 
CDCA3 cell division cycle associated 3 0.046 0.55 -1.80 
POLR3K polymerase (RNA) III (DNA directed) polypeptide K, 12.3 kDa 0.047 0.67 -1.49 
RAB3IL1 RAB3A interacting protein (rabin3)-like 1 0.050 0.69 -1.46 
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KIAA0020 Pumilio domain-containing protein KIAA0020 0.0003 8.65 8.65 
CTTN cortactin, transcript variant 2 0.003 2.31 2.31 
MTA1 Metastasis-associated protein 0.003 1.76 1.76 
RTN4IP1 Reticulon-4-interacting protein 1 0.005 1.66 1.66 
BRSK2 BR serine/threonine kinase 2 0.005 3.01 3.01 
PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma) 0.007 1.82 1.82 
FCHSD1 FCH and double SH3 domains 1 0.008 1.46 1.46 
DUSP22 dual specificity phosphatase 22 0.009 2.16 2.16 
NR4A1 nuclear receptor subfamily 4, group A, member 1, transcript variant 1 0.011 1.64 1.64 
RASL11B RAS-like, family 11, member B 0.013 1.82 1.82 
CENTD2 centaurin, delta 2 0.014 1.58 1.58 
DBR1 Lariat debranching enzyme 0.015 2.64 2.64 
CCDC69 coiled-coil domain containing 69 0.015 2.16 2.16 
SELK Selenoprotein K 0.015 1.58 1.58 
UTP18 U3 small nucleolar RNA-associated protein 18 homolog 0.016 1.57 1.57 
C20orf18 RanBP-type and C3HC4-type zinc finger-containing protein 1 0.016 2.10 2.10 
SCG3 secretogranin III 0.016 2.10 2.10 
MGC50811 Uncharacterized protein C2orf62 0.017 2.04 2.04 
CDK7 cyclin-dependent kinase 7 (MO15 homolog, Xenopus laevis, cdk-activating kinase) 0.018 1.42 1.42 
SCYE1 small inducible cytokine subfamily E, member 1 (endothelial monocyte-activating) 0.020 1.42 1.42 
FLJ46266 FLJ46266 protein, mRNA. 0.020 1.68 1.68 
H2AFY2 H2A histone family, member Y2 0.021 1.54 1.54 
RGS10 regulator of G-protein signaling 10, transcript variant 1 0.022 2.30 2.30 
CPEB4 Cytoplasmic polyadenylation element-binding protein 4 0.022 1.52 1.52 
CHCHD2 coiled-coil-helix-coiled-coil-helix domain containing 2 0.025 2.02 2.02 
SF1 Splicing factor 1 0.026 1.31 1.31 
 















































C17orf44 chromosome 17 open reading frame 44 0.026 1.43 1.43 
ODF3L2 Outer dense fiber protein 3-like protein 2 0.027 1.44 1.44 
WWOX WW domain containing oxidoreductase, transcript variant 3 0.028 1.72 1.72 
HTF9C HpaII tiny fragments locus 9c protein 0.033 1.71 1.71 
VSTM2 V-set and transmembrane domain containing 2A 0.034 2.26 2.26 
MGC31957 hypothetical protein MGC31957 0.038 1.96 1.96 
TMEM136 transmembrane protein 136 0.038 1.37 1.37 
PLK2 Serine/threonine-protein kinase 0.038 1.46 1.46 
MIER1 mesoderm induction early response 1 homolog (Xenopus laevis) 0.039 1.79 1.79 
SUV420H1 suppressor of variegation 4-20 homolog 1 (Drosophila) 0.040 1.28 1.28 
CENTG2 centaurin, gamma 2 0.040 3.46 3.46 
BTN1A1 Butyrophilin subfamily 1 member A1 0.041 1.84 1.84 
IMP3 IMP3, U3 small nucleolar ribonucleoprotein, homolog (yeast) 0.041 1.43 1.43 
CCDC82 coiled-coil domain containing 82 0.042 1.56 1.57 
RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 0.044 1.55 1.55 
ZMYND11 zinc finger, MYND domain containing 11 0.044 1.30 1.30 
PSMA3 proteasome (prosome, macropain) subunit, alpha type, 3 0.044 1.56 1.56 
C8orf53 chromosome 8 open reading frame 53 0.045 1.40 1.40 
ARID3B AT rich interactive domain 3B (BRIGHT-like) 0.046 2.25 2.25 
SULF2 sulfatase 2 0.046 1.33 1.34 
LRRC1 leucine rich repeat containing 1 0.049 2.09 2.09 
SMYD2 SET and MYND domain-containing protein 2 0.049 3.43 3.43 
CDC7 Cell division cycle 7-related protein kinase 0.049 1.39 1.39 
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3 Table A3 ANOVA analysis of proteins identified on proto-array using published gene expression microarray dataset. Each protein was subjected to 
4 further analysis of its expression in B-ALL compared with healthy pre-B bone marrow cells using microarray data from GSE38403.(Geng et al., 2012) The 
5 tables show associations between antigen expression and (A) disease stage or (B) cytogenetic abnormalities. Cells highlighted are those that have a p value of 
6 <0.05. Values in parenthesis indicate whether the relationship between gene expression and the feature is significant (p value of <0.05) and positive (1) 










































































































ACOX1 0.06 0.03 (-1) 0.42 (-1) 0.10 (-1) 0.14 (-1) 0.96 (-1) 0.29 (1) 0.43 (1) 0.19 (1) 0.03 (1) 0.53 (-1) 0.67 (-1) 0.44 (1) 0.73 (1) 0.11 (1) 0.15 (1) 
APOBEC3A 2.00E-03 0.13 (1) 0.36 (-1) 0.64 (1) 0.05 (1) 0.70 (-1) 0.01 (-1) 0.04 (-1) 0.21 (1) 0.04 (-1) 0.10 (1) 1.86E-03 (1) 0.60 (1) 0.01 (1) 0.34 (-1) 0.01 (-1) 
BMX 0.64 0.91 (1) 0 .42 (1) 0.41 (1) 0.88 (1) 0.68 (1) 0.32 (1) 0.12 (1) 0.92 (1) 0.65 (1) 0.83 (-1) 0.37 (-1) 0.69 (-1) 0.24 (-1) 0.77 (-1) 0.71 (1) 
CDC42EP1 0.11 0.02 (1) 0.19 (1) 0.03 (1) 0.14 (1) 0.48 (1) 0.64 (-1) 0.78 (1) 0.13 (-1) 0.19 (-1) 0.58 (1) 0.82 (-1) 0.53 (-1) 0.17 (-1) 0.18 (-1) 0.56 (-1) 
CDCA3 0.41 0.18 (1) 0.99 (1) 0.45 (1) 0.49 (1) 0.53 (1) 0.19 (-1) 0.31 (-1) 0.20 (-1) 0.64 (-1) 0.45 (1) 0.49 (1) 0.54 (1) 0.89 (-1) 0.97 (1) 0.91 (1) 
DCTPP1 3.84E-03 0.39 (-1) 0.04 (-1) 0.16 (-1) 0.02 (-1) 0.50 (-1) 0.05 (-1) 0.20 (-1) 3.66E-04 (-1) 0.94 (-1) 0.22 (1) 0.76 (1) 0.17 (1) 0.10 (-1) 0.60 (1) 0.14 (1) 
GAK 0.55 0.26 (-1) 0.38 (-1) 0.72 (-1) 0.43 (-1) 0.91 (-1) 0.92 (-1) 0.14 (1) 0.54 (1) 0.33 (1) 0.44 (1) 0.72 (1) 0.44 (1) 0.47 (-1) 0.82 (1) 0.52 (1) 
GCC1 0.16 0.22 (-1) 0.34 (-1) 0.06 (-1) 0.52 (-1) 0.93 (-1) 0.91 (-1) 0.09 (-1) 0.24 (1) 0.27 (1) 0.49 (-1) 0.54 (1) 0.38 (1) 0.03 (1) 0.07 (1) 0.60 (1) 
IGLL1 0.20 0.46 (-1) 0.78 (-1) 0.16 (-1) 0.97 (1) 0.35 (-1) 0.72 (1) 0.13 (-1) 0.09 (1) 0.59 (-1) 0.30 (-1) 0.70 (1) 0.51 (-1) 0.01 (1) 0.84 (1) 0.22 (-1) 
LMX1A 0.17 0.65 (1) 0.21 (1) 0.30 (1) 0.19 (1) 0.23 (1) 0.20 (1) 0.18 (1) 0.04 (1) 0.23 (1) 0.57 (-1) 0.76 (-1) 0.96 (-1) 0.64 (1) 0.62 (1) 0.81 (1) 
LMX1A† 0.90 0.33 (1) 0.48 (1) 0.47 (1) 0.49 (1) 0.86 (1) 0.99 (1) 0.71 (-1) 0.61 (-1) 0.47 (-1) 0.86 (-1) 0.82 (-1) 0.59 (-1) 0.93 (-1) 0.62 (-1) 0.65 (-1) 
MUC20 1.47E-04 0.62 (1) 0.05 (1) 0.41 (1) 0.01 (1) 0.34 (1) 0.02 (1) 0.44 (1) 5.89E-06 (1) 0.42 (1) 0.08 (-1) 0.90 (-1) 0.29 (-1) 4.91E-03 (1) 0.69 (1) 0.22 (-1) 
NAT1 0.01 0.13 (-1) 0.02 (-1) 0.03 (-1) 0.56 (-1) 0.94 (-1) 0.09 (-1) 0.10 (-1) 0.05 (1) 0.16 (1) 0.42 (1) 0.02 (1) 0.03 (1) 0.01 (1) 0.04 (1) 0.63 (1) 
SEPT9 1.69E-03 0.30 (-1) 0.87 (-1) 0.64 (-1) 0.41 (1) 0.57 (1) 0.42 (1) 0.28 (1) 4.80E-05 (1) 0.07 (1) 0.80 (-1) 0.30 (1) 0.46 (1) 0.03 (1) 0.23 (1) 0.94 (-1) 
RAB3IL1 0.67 0.49 (1) 0.55 (1) 0.23 (1) 0.44 (1) 0.87 (-1) 0.88 (1) 0.22 (1) 0.78 (1) 0.36 (-1) 0.67 (1) 0.98 (-1) 0.44 (-1) 0.43 (-1) 0.16 (-1) 0.33 (-1) 
TOX2 1.29E-03 0.42 (1) 0.26 (-1) 0.70 (-1) 0.53 (-1) 0.38 (-1) 0.02 (-1) 0.01 (-1) 1.41E-03 (-1) 0.04 (-1) 0.29 (1) 0.41 (1) 0.81 (1) 0.68 (-1) 0.46 (-1) 0.61 (-1) 
VGLL4 0.01 0.58 (-1) 0.18 (1) 0.80 (-1) 0.72 (-1) 0.07 (1) 0.02 (-1) 0.57 (1) 0.70 (1) 2.73E-03 (1) 0.05 (-1) 0.04 (-1) 0.65 (1) 0.87 (-1) 0.01 (1) 0.01 (1) 
WARS 3.02E-03 0.65 (-1) 0.02 (-1) 0.14 (-1) 0.19 (-1) 0.09 (-1) 3.69E-03 (-1) 0.02 (-1) 0.04 (-1) 0.05 (-1) 0.10 (1) 0.06 (1) 0.47 (1) 0.74 (1) 0.47 (-1) 0.36 (-1) 
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(neg vs. pos) 
ACOX1 0.56 (-1) 0.16 (1) 0.07 (-1) 0.56 (1) 0.007 (1) 0.54 (-1) 0.75 (-1) 0.4 (-1) 
APOBEC3A 0.31 (1) 0.01 (1) 0.012 (-1) 0.24 (-1) 0.37 (-1) 0.57 (1) 0.2 (1) 0.5 (-1) 
BMX 0.001 (-1) 0.83 (-1) 0.31 (-1) 0.45 (1) 0.11 (-1) 0.36 (-1) 0.27 (1) 0.14 (1) 
CDC42EP1 0.51 (1) 0.04 (-1) 0.32 (1) 0.71 (1) 0.11 (-1) 0.65 (1) 0.41 (1) 0.13 (1) 
CDCA3 0.61 (-1) 0.51 (-1) 0.14 (1) 0.53 (-1) 0.008 (-1) 0.41 (1) 0.95 (1) 3.73E-05 (1) 
DCTPP1 0.09 (-1) 9.39E-07 (-1) 5.03E-05 (1) 0.39 (1) 0.89 (-1) 0.55 (1) 0.45 (-1) 0.47 (1) 
GAK 0.87 (-1) 0.39 (-1) 0.023 (1) 0.32 (1) 0.09 (1) 0.23 (-1) 0.044 (-1) 0.18 (1) 
GCC1 0.98 (-1) 0.38 (1) 0.097 (1) 0.12 (-1) 0.18 (-1) 0.17 (-1) 0.1 (-1) 0.0024 (1) 
IGLL1 0.03 (1) 0.09 (1) 1.17E-05 (1) 0.59 (-1) 0.024 (-1) 0.049 (1) 7.76E-07 (-1) 1.93E-05 (-1) 
LMX1A 0.07 (1) 0.01 (1) 2.33E-08 (-1) 0.26 (-1) 0.0005 (-1) 0.1 (1) 0.002 (1) 0.03 (1) 
LMX1A† 0.49 (1) 0.69 (-1) 0.06 (1) 0.53 (1) 0.73 (1) 0.54 (1) 0.43 (-1) 0.1 (-1) 
MUC20 0.56 (-1) 0.0001 (1) 0.09 (-1) 0.84 (-1) 0.04 (-1) 0.28 (1) 0.66 (-1) 0.65 (-1) 
NAT1 0.91 (1) 0.11 (1) 0.1 (-1) 0.51 (-1) 0.7 (-1) 0.56 (-1) 0.62 (1) 0.25 (1) 
RAB3IL1 0.34 (1) 0.1 (1) 0.9 (1) 0.24 (-1) 0.31 (-1) 0.86 (-1) 0.03 (-1) 0.95 (-1) 
SEPT9 0.53 (1) 0.02 (1) 0.93 (-1) 0.84 (1) 0.43 (1) 0.03 (-1) 0.08 (-1) 0.4 (-1) 
TOX2 0.9 (-1) 0.0006 (-1) 1.01E-13 (1) 0.29 (-1) 0.07 (-1) 0.7 (-1) 9.54E-05 (-1) 6.07E-14 (1) 
VGLL4 0.43 (1) 0.49 (-1) 0.004294 (-1) 0.13 (-1) 0.02 (1) 0.34 (1) 0.01 (1) 0.018 (-1) 
WARS 0.93 (1) 0.41 (-1) 0.09 (1) 0.049 (1) 0.5 (1) 0.97 (1) 0.08 (-1) 0.42 (1) 
 
































British Journal of 
 
 British Journal of 
Haematology 





2   
3   
4   
5   
6   
7   
8   
9   
10   
11   
12   
13   
14   
15   
16   
17   
18   
19   
20   
21   
22   
23   
24   
25   
26   
27   
28   
29   
30   
31   
32   
33   
34   
35   
36   
37   
38   
39   
40   
41   
42   
43   
44   
45   
46   
47   
48   
49   
50   
51   
52   
53   
54   
55   
56   
57   
58   
59   




































27 Fig 1 Immunoprofiling using sera from adult B-ALL patients and HVs. (A) Hierarchal Clustering of proteins 
28 shows that adult B-ALL and HV samples may be differentiated based on antibody recognition of antigens and 
29 that antigen recognition to adult B-ALL sera (blue box) may be less heterogeneous than previously thought; 































































25 (B) PCA evidences the distinctness of features of samples from HVs (blue circles) and patient samples (red 
26 circles) bar one HV sample. 
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13 Fig 2. Analysis of the protein interactions and gene expression of prioritised antigens. (A) STRING analysis 
14 identified the experimentally determined protein interactions by each antigen of interest (represented as a 15 red ball). Panel (i) BMX showed interactions with multiple components involved in cell-adhesion, cell growth, 
16 cell survival, signaling pathways and apoptosis, including ES1, FYN, SRC and CASP3; Panel (ii) DCTPP1 (red 17 ball) interacts with NME1 and 2. NME1 is involved in cell proliferation, differentiation and development while 
18 NME2 acts as a transcriptional activator for the MYC gene, a family of regulator genes and proto-oncogenes; 
Panel (iii) VGLL4 interacts with TEA domain family members (TEAD1, 2 and 4), transcriptional factors that 
play key roles in the Hippo signaling pathway. The Hippo pathway is involved in controlling tumor 
20 suppression by restricting proliferation and promoting apoptosis; 
21 


















































































35 (B) Expression of each antigen is shown as follows (i) BMX; (ii) DCTPP1; (iii) Survivin and (iv) VGLL4 


























































25 Fig 3. Immunolabelling to detect expression of the prioritised antigens in primary adult B-ALL patient 
26 samples. Blue arrows indicate the B-ALL patient cells that show antigen expression (also indicated by the 
27 formation of a brown precipitate). Actin acted as the positive control for immunolabelling. The two isotype 
matched antibodies were used as negative controls. Panel (A) shows patient and HV samples 
29 immunolabelled for expression of BMX, DCTPP1, survivin and VGLL4 while 



















































































45 panel (B) shows samples immunolabelled for BMX expression and with isotype control antibody only. 
46 Percentages shown are the averages of positively stained cells of the ‘n’ independent experiments. The blue 
47 arrows point at positive stained cells and the blue squares contain one-cell-zoom pictures from the original 
48 picture (scale bar is 100µm). All pictures were taken at 400X magnification. 

















































29 Fig 4. Gene expression microarray analysis of antigen expression and overall survival (over 5 years) in adult 
30 B-ALL patients.  Overall survival  was found to be significantly associated with above median (high) levels of 
31 (A)(i) TOX2 (Log-Rank p-value = 0.075; Wilcoxon-Gehan p-value = 0.034) and (ii) GAK (Log-Rank p-value 
32 0.024; Wilcoxon-Gehan p-value = 0.034);  When expression levels were divided into quartiles (B) Q1 
33 represents low-low level expression, Q2 median-low; Q3 median-high and Q4 high-high levels of expression, 
34  relative to the median. (i) TOX2 expression was significantly associated with improved survival for the 
patients expressing median-high (Q3) levels of expression (Log-Rank p-value 0.011; Wilcoxon-Gehan p- 
value = 0.032) but not for patients expressing the high-high levels (Q4). The same association was not seen 
36 with (ii) GAK expression although a trend towards improved survival was seen in patients with the high-high 
37 levels of expression (Log-Rank p-value = 0.11; Wilcoxon-Gehan p-value = 0.19). 
38 










































13 Fig 2. Analysis of the protein interactions and gene expression of prioritised antigens. (A) STRING analysis 
14 identified the experimentally determined protein interactions by each antigen of interest (represented as a 15 red ball). Panel (i) BMX showed interactions with multiple components involved in cell-adhesion, cell growth, 
16 cell survival, signaling pathways and apoptosis, including ES1, FYN, SRC and CASP3; Panel (ii) DCTPP1 (red 17 ball) interacts with NME1 and 2. NME1 is involved in cell proliferation, differentiation and development while 
18 NME2 acts as a transcriptional activator for the MYC gene, a family of regulator genes and proto-oncogenes; 
Panel (iii) VGLL4 interacts with TEA domain family members (TEAD1, 2 and 4), transcriptional factors that 
play key roles in the Hippo signaling pathway. The Hippo pathway is involved in controlling tumor 
20 suppression by restricting proliferation and promoting apoptosis; 
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